Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of OPS-2071 in healthy Japanese males
NCT02440633Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- May 2015
- Primary completion
- Aug 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OPS-2071 in bacterial enteritis, sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: The Amounts of Radioactivity Excreted in Urine and Faeces, Area Under Curve (AUC) of Total Radioactivity in Plasma and Whole Blood and 1 more. Started May 2015; status: completed.
02
Drugs
OPS-2071
03
Conditions
bacterial enteritis
Beyond the preview
Go deeper on NCT02440633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02440633.